Rh-induced hemolytic disease of the newborn; Erythroblastosis fetalis
Rh incompatibility is a condition that develops when a pregnant woman has Rh-negative blood and the baby in her womb has Rh-positive blood.
During pregnancy, red blood cells from the unborn baby can cross into the mother's blood through the placenta.
If the mother is Rh-negative, her immune system treats Rh-positive fetal cells as if they were a foreign substance. The mother's body makes antibodies against the fetal blood cells. These antibodies may cross back through the placenta into the developing baby. They destroy the baby's circulating red blood cells.
When red blood cells are broken down, they make bilirubin. This causes an infant to become yellow (jaundiced). The level of bilirubin in the infant's blood may range from mild to dangerously high.
Firstborn infants are often not affected unless the mother had past miscarriages or abortions. This would sensitize her immune system. This is because it takes time for the mother to develop antibodies. All children she has later who are also Rh-positive may be affected.
Rh incompatibility develops only when the mother is Rh-negative and the infant is Rh-positive. This problem has become less common in places that provide good prenatal care. This is because special immune globulins called RhoGAM are routinely used.
Rh incompatibility can cause symptoms ranging from very mild to deadly. In its mildest form, Rh incompatibility causes the destruction of red blood cells. There are no other effects.
After birth, the infant may have:
- Yellowing of the skin and whites of the eyes (jaundice)
- Low muscle tone (hypotonia) and lethargy
Exams and Tests
Rh incompatibility can be prevented with the use of RhoGAM. Therefore, prevention remains the best treatment. Treatment of an infant who is already affected depends on the severity of the condition.
Infants with mild Rh incompatibility may be treated with phototherapy using bilirubin lights. IV immune globulin may also be used. For infants severely affected, an exchange transfusion of blood may be needed. This is to decrease the levels of bilirubin in the blood.
Full recovery is expected for mild Rh incompatibility.
Complications may include:
- Brain damage due to high levels of bilirubin (kernicterus)
- Fluid buildup and swelling in the baby (hydrops fetalis)
- Problems with mental function, movement, hearing, speech, and seizures
When to Contact a Medical Professional
Call your health care provider if you think or know you are pregnant and have not yet seen a provider.
Rh incompatibility is almost completely preventable. Rh-negative mothers should be followed closely by their providers during pregnancy.
Special immune globulins, called RhoGAM, are now used to prevent RH incompatibility in mothers who are Rh-negative.
If the father of the infant is Rh-positive or if his blood type is not known, the mother is given an injection of RhoGAM during the second trimester. If the baby is Rh-positive, the mother will get a second injection within a few days after delivery.
These injections prevent the development of antibodies against Rh-positive blood. However, women with Rh-negative blood type must get injections:
- During every pregnancy
- After a miscarriage or abortion
- After prenatal tests such as amniocentesis and chorionic villus biopsy
- After injury to the abdomen during pregnancy
Kaplan M, Wong RJ, Burgis JC, Sibley E, Stevenson DK. Neonatal jaundice and liver diseases. In: Martin RJ, Fanaroff AA, Walsh MC, eds. Fanaroff and Martin's Neonatal-Perinatal Medicine. 11th ed. Philadelphia, PA: Elsevier; 2020:chap 91.
Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM. Blood disorders. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 124.
Moise KJ. Red cell alloimmunization. In: Landon MB, Galan HL, Jauniaux ERM, et al, eds. Gabbe's Obstetrics: Normal and Problem Pregnancies. 8th ed. Philadelphia, PA: Elsevier; 2021:chap 40.
Last reviewed on: 2/2/2021
Reviewed by: Neil K. Kaneshiro, MD, MHA, Clinical Professor of Pediatrics, University of Washington School of Medicine, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.